Compound Kushen injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A meta-analysis of 37 RCTs following the PRISMA guidelines

Objective: Compound Kushen injection (CKI), one of the commonly used antitumor Chinese patent medicines, has been widely prescribed as adjunctive treatment to platinum-based chemotherapy (PBC) in patients with advanced non-small cell lung cancer (NSCLC). However, the efficacy and safety of this comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hongwei, Yao, Xiaojun, Li, Ting, Lam, Christopher Wai-Kei, Zhang, Ruonan, Zhang, Huixia, Wang, Jue, Zhang, Wei, Leung, Elaine Lai-Han, Wu, Qibiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052862/
https://www.ncbi.nlm.nih.gov/pubmed/32194799
http://dx.doi.org/10.7150/jca.40267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052862/
https://www.ncbi.nlm.nih.gov/pubmed/32194799
http://dx.doi.org/10.7150/jca.40267

Ejemplares similares